Ulcerative colitis and multiple sclerosis are two autoimmune conditions. People with ulcerative colitis may be at an increased risk of multiple sclerosis, but the opposite doesn’t seem to be true.

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...